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Abstract
Background: Colorectal carcinoma is a common and often fatal disease in which methods of early detection and
monitoring are essential. The present study was conducted for measuring serum levels of nucleosomes,
carcinoembryonic antigen (CEA) and CA 19-9 in patients newly diagnosed with colorectal carcinoma and
confirmed by clinicopathological study.
Method: Thirty subjects were included in the current study: six normal subjects as a control group with mean age
(45.6 ± 7.9) and twenty four colorectal carcinoma patients with mean age (46.9 ± 15.6), which were classified
pathologically according to the degree of malignant cell differentiation into well differentiated (group I),
moderately differentiated (group II) and poorly differentiated (group III). Fasting venous blood samples were
collected preoperative.
Results: The results revealed a significant increase in serum level of nucleosomes in patients with poorly
differentiated tumors versus patients with well differentiated tumors (p = 0.041). The levels of CEA and CA19-9
showed no significant increase (p = 0.569 and 0.450, respectively).
Conclusion: In conclusion, serum level of nucleosomes provides a highly sensitive and specific apoptotic marker
for colorectal carcinoma.
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Background
Colorectal carcinoma is one of the leading causes of
cancer-related death [1,2]. The 5-year survival rate for
colon tumours in Europe ranges from 26% to 56% for
men and from 29% to 59% for women. These differ-
ences in survival have been attributed to the stage and
timing of diagnosis and, in some regions, to the quality
of medical care [3]. Hence the need for early detection
methods in colorectal cancer [4].
Tumor markers are used clinically for diagnosis, sta-
ging, and monitoring of the disease. They are proteins
released from dying tumor cells or produced by neo-
plastic cells. There are two subcategories of these pro-
teins, specific and non-specific. The specific proteins
are expressed only in the tumor cells and are very use-
ful for the detection and diagnosis of specific malig-
nant tumors. Non-specific proteins or markers related
to malignant cells are oncofetal or carcinogenic anti-
gens, such as carcinoembryonic antigen (CEA), alpha-
fetoprotein (AFP), prostate specific antigen (PSA),
carbohydrate antigens CA15.3 and CA19-9. Recently
nucleosomes, cytokeratine 18, and cyto-c in serum
have been examined as markers for the evaluation of
apoptotic death [5].
The basic unit of chromatin, known as a nucleosome,
is composed of local wrapping of a short stretch of dou-
ble stranded (ds) DNA (147 bp in length) around an
octameric histone protein core of two molecules each of
histones H2A, H2B, H3 and H4 (known as nucleosome
core particle (NCP)), and the so-called linker DNA that
varies between 10 and 100 bp and connects neighboring
nucleosomes in a chain like pattern [6].
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multicellular organisms to remodel tissue during devel-
opment. It maintains tissue homeostasis (proliferation
and apoptosis balance) by removing senescent cells and
deleting cells with irreparable genetic damage. It is a
highly regulated process with distinct morphologic and
biochemical features [7,8].
The mechanism of apoptosis in tumors is unclear.
However, it is known to be p53 and caspases dependent
[9], a hallmark of cancer cells [10]. During apoptosis,
caspases are activated leading to degradation of cell con-
stituents [11]. High levels of circulating mono- and
oligo-nucleosomal fragments are expected. In blood, cir-
culating nucleic acids are not digested by endonucleases
due to their close association with histone protein. High
levels of circulating DNA fragments have been found in
the blood of patients with most types of malignancy
including colorectal, lung, gastrointestinal, breast, gyne-
cological, renal, and nasopharyngeal cancers as well as
lymphoma [12,13].
For colorectal cancer many biomarkers have been
assessed but only a small number have been recom-
mended for clinical use. The aim of the present study
was to compare the circulating levels of nucleosomes,
CEA and CA 19-9 as apoptotic markers of colorectal
carcinoma and to determine which one is more specific
and sensitive for clinical use.
CEA is a product of columnar and goblet cells in the
normal colon cells as well as colonic cancer cells with a
half life of 3-11 days. It is a glycoprotein with a molecu-
lar weight of 200 kDa; most of its carbohydrate content
is composed of mannose, galactose, N-acetylglucosa-
mine, fructose and sialic acid [14]. The serum levels of
CEA may increase 4.5 to 8 months before the develop-
ment of cancer symptoms. Therefore, CEA monitoring
is the most cost-effective indicator for the disease [15].
CA 19-9 is an antigen originally isolated for the first
time from human colorectal carcinoma, which is identi-
fied by monoclonal antibody designated 19-9. It was
postulated that CA 19-9 could not be recommended for
early diagnosis of colorectal carcinoma and its serial
determination appears to provide little information to
that of CEA in monitoring patients [16].
Methods
The present study was conducted in patients with colorec-
tal cancer admitted to the Gastroenterology Department
of EI-Minia University Hospital. Twenty four patients
were included in the study (ten females and fourteen
males) with ages ranging from 34 to 72 years (mean 46.9 ±
15.6). Six normal subjects were selected as a control group.
All patients proved to have colorectal carcinoma by his-
tory, examination, investigations and biopsy. The blood
samples were collected before surgical interference.
The circulating levels of nucleosomes were estimated
by cell death detection ELISA (CDDE)
plus supplied from
Roche Diagnostic-Germany. CEA and CA 19-9 serum
levels were determined by electrochemi-luminescence
immunoassay (ECLISA) on Roche Elecsys 1010 immu-
noassay analyzer. The kits were used according to the
manufacturer’s instructions. The chemicals were sup-
plied by Roche Diagnostics GmbH, D 68298, Mannheim,
Germany. The patients were classified into three groups,
nine patients with well differentiated tumor, nine
patients with moderately dif f e r e n t i a t e dt u m o ra n ds i x
patients with poorly differentiated tumor according to
The Modified Dukes classification of Astler and Coller
[17].
Statistical methods
To test for normal distribution, frequency of data was
plotted against normal distribution curve. Nonpara-
metric statistical methods were used. Frequency, med-
ian, range and standard error of means were used to
describe data. Kruskal-Wallis, nonparametric analysis of
variance was used to test for variability between groups
in quantitative variables while, Mann-Whitney u test
was used to test for significance of difference in quanti-
tative variables between each two groups. Nonpara-
metric Kendall’s correlation was used to test for linear
relationship between different quantitative variables.
Regression analysis was used for further analysis of the
linear relationship between nucleosomes, CEA and CA
19-9. Receiver operating characteristic (ROC) curve ana-
lysis was done using MedCalc software for evolution of
sensitivity and specificity of different markers. P value
was considered significant if less than 0.05. These tests
were run on an IBM compatible personal computer
using the Statistical Package for Social Scientists (SPSS)
for windows 7.5 (SPSS Inc., Chicago, IL, USA).
Results
Table (1) shows range, median and SE of the studied
parameters in control versus patient groups (well,
moderately and poorly differentiated tumors). There is
significant increase in nucleosomes levels in all groups
versus the control group (P < 0.001). CEA levels show
a significant increase in all groups except the poorly
differentiated tumor group versus the control group (P
< 0.001 for the well differentiated tumor group, 0.037
for the moderately differentiated tumor group and
0.106 for the poorly differentiated tumor group). There
is no significant increase in the levels of nucleosomes,
also, no significant decrease in the levels of CEA with
decreased grade of tumor differentiation. There is
significant increase in the levels of nucleosomes in
poor differentiated versus well differentiated tumors
(p = 0.041).
Al-Shuneigat et al. Journal of Biomedical Science 2011, 18:50
http://www.jbiomedsci.com/content/18/1/50
Page 2 of 5The overall positive rates obtained from ROC curve
(Figure 1) of circulating CEA and CA 19-9 (using the
cutoff values of 3.56 ng/ml and 28 U/ml, respectively)
were 56.2% and 36.4% (Table 2).
Table (2) shows statistical evaluation of nucleosomes
in comparison to CEA and CA 19-9 for colorectal carci-
noma. By all statistical parameters, nucleosomes show
the best values. As regards kappa it shows an excellent
agreement between laboratory and actual diagnosis for
nucleosomes while the values of CEA and CA 19 -9
show only weak agreement.
The curve shows the true positive rate (sensitivity)
plotted versus false positive rate (100-specificity) for dif-
ferent cutoff points for nucleosomes, CEA and CA 19-9.
Discussion
Nuclear fragmentation as one of the morphologic fea-
tures of apoptosis, results in a characteristic pattern of
DNA complexed with histone proteins known as
nucleosomes [18]. The measurement of these nucleo-
somes constitutes a feasible parameter for late stage of
apoptosis [19]. Circulating nucleosomes can be quanti-
fied by real time PCR of the DNA. Moreover they can
be estimated by stable immunologic assays that are par-
ticularly well suited for serial measurements.
CEA is a member of the immunoglobulin superfamily
which was originally identified in human fetal colon and
colorectal cancer. It is widely used as a tumor marker.
However, little is known about its function except that
it acts as a homotypic adhesion molecule that is impli-
cated in cell aggregation [20]. It is over-expressed in
Table 1 Comparison between serum levels of nucleosomes, CEA and CA 19-9 in the three patient groups versus the
control group and each group of patients versus the other groups
Parameters
Groups
Nucleosomes
(AU)
CEA
(ng/ml)
CA 19-9
U/ml
Control group (n = 6) Median 282.6 2.3 20.9
S.E ± 26.4 0.39 3.2
Range Min. 181.5 0.8 7.8
Max. 519.2 4.2 41.4
Group I Patients (well differentiated tumor) (n = 9) Median 1081 6.6 32.86
S.E ± 209.5 9.00 101.6
Range Min. 712.4 1.29 8.4
Max. 3382.5 1729 1895
Group II Patients Median 1776.2 4.61 23.9
(moderate differentiated tumor) (n = 9) S.E ± 171.3 75.6 64.6
Range Min. 772.2 1.6 1.6
Max. 3426.9 2400 2246
Group III Median 1860 4.6 34
Patients (poor differentiated tumor) (n = 6) S.E ± 260.6 6.26 44.66
Range Min. 1149.7 1.72 3.16
Max. 3482.5 52.6 386.2
P control versus group I <0.001 <0.001 0961
P control versus group II <0.001 0.037 0.666
P control versus group III <0.001 0.106 0.816
P group I versus group II 0.086 0.464 0.116
P group I versus group III 0.041 0.569 0.450
P group II versus group III 0.566 0.861 0.627
Figure 1 Receiver operating characteristic curve (ROC) of
nucleosomes, CEA and CA 19-9 in colorectal carcinoma
diagnosis.
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surface of cancer cells. It was reported that the over
expression of CEA can protect cancer cells from apopto-
sis while a decrease in expression might lead to new
approaches for management of cancer colon and other
organs [21]. CEA is produced by more than 90% of col-
orectal cancers and contributes to the malignant charac-
teristics of this type of cancer [22].
Although colorectal cancer screening is recommended
for persons over 50 years and older its use is still low
especially among older individuals [23].
An ideal tumor marker would be inexpensive screen-
ing that may help for early diagnosis in population at
risk of cancer. Unfortunately currently available serolo-
gical markers for colorectal carcinoma have not proven
to be ideal [24].
The levels of serum nucleosomes show significant
increase in patients as compared to control group
(Table 1) with excellent discrimination between the two
(area under curve equals 1 in table 2) that agrees with
other published data [25]. There is an association of
high nucleosomes levels with advanced stages of color-
ectal carcinoma. This may be due to a delayed clearance
of nucleosomes from circulation where the bulky tumor
tends to undergo peripheral apoptosis and central
necrosis that in its turn would elicit local and systemic
inflammatory responses and hence higher nucleosomes
production [26].
The relationship between apoptosis and the degree of
cell differentiation may play an important role in the
susceptibility of the tumor cells to apoptosis [27]. An
immature phenotype represents a block in the normal
differentiation pathway [28]. Also, another study
observed that the more the colon cells are stimulated to
differentiate, the less likely they are to proliferate and
hypothetically, the higher their rate of apoptosis [29].
After complete tumor resection of colorectal cancer, it
was noticed that the level of nucleosomes increased in
most patients rapidly reaching a maximum level during
the first day. This was followed by a subsequent
decrease, while the level was lower than in patients with
postoperative or relapse therapy [30].
In the current study, the overall positive rates
obtained from ROC curve (Figure 1) of circulating CEA
and CA 19-9 (using the cutoff values of 3.56 ng/ml and
28 U/ml, respectively) were 56.2% and 36.4% (Table 2).
These levels are higher than those reported by Zheng et
al [24] who gave positive values of 29.2% and 25.2% for
CEA and CA 19-9, their cutoff values of 5 ug/l and 31
Ku/l respectively. While the positive rates reported by
Chan and Sell,[31], were 70% and 30% for CEA and CA
19-9, the cutoff values were of 3.5 ug/l and 37 Ku/l,
respectively. CEA in the current study can provide a
better discrimination between control subjects and
patients than CA 19-9 (the areas under the ROC curve
were 0.808 and 0.524 for CEA and CA 19-9,
respectively).
Table (1) shows no significant difference in the levels
of CA 19-9 in patients as compared to the control
group while CEA shows a difference. Bhatnagar et al
[32] noticed that in the well differentiated colorectal
carcinoma there is more production of CEA/gram of
total protein than in the poorly differentiated tumors in
agreement with results obtained in the present study.
On the other hand, it was observed that there is no sig-
nificant correlation between levels of serum CA 19-9
and CEA [22] and the differentiation degree of the
tumor.
Conclusion
In conclusion, our study confirms that the levels of
nucleosomes provide highly specific and sensitive apop-
totic marker for colorectal carcinoma which should be
applied on a large scale of cancers with respect to clini-
copathological variables. It can be used - for diagnosis,
screening, prognosis, and in therapy monitoring.
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Table 2 Statistical evaluation of nucleosomes compared to CEA and CA 19-9 for colorectal carcinoma
Parameter Cutoff value Sensitivity % Specificity % J index Accuracy % Kappa PPV % NPV % ROC
curve area
Value P
CA 19-9 28 u/ml 36.4 88.9 26 41 0.121 0.088 91.56 21.62 0.524
CEA 3.56 ng/ml 56.2 100 55.8 62.2 0.290 <0.001 100 30.40 0.808
Nucleosomes 421 100 100 100 100 1.00 <0.001 100 100 1.0
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